Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 5, 2024 6:54 AM EDT
Oppenheimer analyst Leland Gershell upgraded Ascendis Pharma (NASDAQ: ASND) from Perform to Outperform with a price target of $180.00.
The analyst comments "We upgrade ASND to Outperform (from Perform) and assign a $180 PT ahead of 1) Yorvipath's US launch for hypoparathyroidism (to commence by 1Q25)... More
September 4, 2024 7:44 AM EDT
Goldman Sachs analyst Chris Shibutani reiterated a Buy rating and $51.00 price target on Royalty Pharma (NASDAQ: RPRX).
The analyst comments "RPRX announced a deal with Ascendis Pharma (ASND, covered by Paul Choi) for capped synthetic royalties on US net sales of Yorvipath, a first-in-class prodrug of parathyroid hormone (PTH 1-34) for adults with... More
September 4, 2024 5:18 AM EDT
Jefferies analyst Kelly Shi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $174.00 (from $196.00) while maintaining a Buy rating.
The analyst comments "Skytrofa experienced a revenue growth reversal in Q2 (26M; -58% Q/Q; -25% YoY) on an unexpected net price... More
September 4, 2024 5:06 AM EDT
Goldman Sachs analyst Paul Choi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $180.00 (from $195.00) while maintaining a Buy rating.
The analyst comments "Miss for Skytrofa on the back of insurance contract resets and significant price pressure; focus remains on upcoming US... More
September 4, 2024 4:57 AM EDT
Citi analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $178.00 (from $193.00) while maintaining a Buy rating.
The analyst comments "Ascendis reported 2Q24 financial results, missing Street estimates on topline revenue and GAAP EPS as the company made significant accounting... More
